文献速递眼底病与葡萄膜炎

棕榈酰乙醇酰胺经PPARα依赖途径抑制视网膜新生血管与纤维化

PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

本研究在大鼠Müller细胞系、氧诱导视网膜病变(OIR)小鼠及VLDLR敲除小鼠中测试棕榈酰乙醇酰胺(PEA)对视网膜新生血管和纤维化的作用。PEA显著减轻炎症、抑制新生血管和促纤维化改变,并抑制Müller胶质增生;其效果依赖PPARα激活,在Pparα-/- OIR小鼠中被取消。PEA可能成为治疗病理性新生血管和纤维化视网膜病变的潜在药物。

要点

  • PEA在OIR和Vldlr-/-小鼠中减轻炎症、抑制新生血管和促纤维化改变。
  • PEA抑制Müller胶质增生,降低炎症因子,且效果依赖PPARα激活。
  • Pparα-/- OIR小鼠中PEA的保护作用被取消,提示PPARα介导。

核心结论

  • PEA通过激活PPARα减少实验性增殖性视网膜病变和新生血管性AMD模型中的视网膜新生血管、纤维化改变及Müller胶质增生。

研究设计与样本

  • 使用大鼠Müller细胞系(rMC-1)、小鼠氧诱导视网膜病变(OIR)模型和极低密度脂蛋白受体(VLDLR)敲除小鼠模型。
  • PEA通过腹腔注射或口服给予动物模型。

主要发现

  • OIR和Vldlr-/-视网膜存在促纤维化改变。
  • PEA显著减轻OIR和Vldlr-/-视网膜的炎症并抑制新生血管。
  • PEA抑制OIR和Vldlr-/-视网膜的促纤维化改变及Müller胶质增生。
  • rMC-1细胞中PEA抑制Müller胶质增生、减少炎症因子并减轻促纤维化改变。
  • PEA治疗提高视网膜PPARα mRNA和蛋白水平,且效果在Pparα-/- OIR小鼠中被取消。

临床怎么用

  • PEA可能作为治疗伴有病理性新生血管和纤维化的视网膜病变(如增殖性视网膜病变和新生血管性AMD)的潜在药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pathological neovascularization and fibrosis are common pathological changes of many retinal diseases, such as proliferative retinopathy (PR) and age-related macular degeneration (AMD). Treatment modalities for these pathological changes are limited. The purpose of the present study was to test the effects of palmitoylethanolamide (PEA), an endocannabinoid mimetic amide, on retinal neovascularization and fibrosis and to determine its molecular mechanism of action. METHODS: A rat Müller cell line (rMC-1), a mouse model of oxygen-induced retinopathy (OIR), and the very-low-density lipoprotein receptor (VLDLR) knockout mouse model were used. PEA was intraperitoneally injected or orally administrated in animal models. Inflammation and profibrotic changes were evaluated by western blot analysis. Glial fibrillary acidic protein (GFAP) and peroxisome proliferator-activated receptor alpha (PPARα) were measured by RT-PCR and western blot analysis. RESULTS: Profibrotic changes were present in OIR and Vldlr-/- retinas. PEA significantly alleviated inflammation and inhibited neovascularization in OIR and Vldlr-/- retinas and suppressed profibrotic changes in OIR and Vldlr-/- retinas. Moreover, PEA potently suppressed Müller gliosis in these retinas. In rMC-1 cells, PEA suppressed Müller gliosis, reduced inflammatory cytokines, and attenuated profibrotic changes. Further, both mRNA and protein levels of PPARα were elevated in the retina under PEA treatment, and the effects of PEA were abolished in Pparα-/- OIR mice. CONCLUSIONS: PEA reduced retinal neovascularization and fibrotic changes and suppressed Müller gliosis in experimental PR and neovascular AMD by activating PPARα. PEA may be a potential treatment for retinopathies with pathological neovascularization and fibrosis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ye S, Chen Q, Jiang N, et al. PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis. Invest Ophthalmol Vis Sci. 2020. PMID: 32298438. doi:10.1167/iovs.61.4.15

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。